Kythera Biopharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Kybella, also known as ATX-101, “for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.” Kybella is the first and only approved non-surgical treatment for reduction of submental fullness, a common yet under-treated aesthetic condition.

For the first time, people have access to an FDA-approved, non-surgical treatment for submental fullness, a condition that can negatively impact the overall appearance of the face and can result in a person feeling older and heavier,” said Keith Leonard, President and Chief Executive Officer of Kythera. “With Kybella, physicians can offer a clinically-proven treatment that is customized to the patient and their treatment goals for an improved chin profile. Importantly, Kybella treatment resulted in high patient satisfaction.”

For more details, go to: http://www.kythera.com/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/